Results 41 to 50 of about 461 (138)

Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM Trial. [PDF]

Circulation
BACKGROUND: Post-exercise oxygen uptake recovery (VO₂Rec) is slow in advanced heart failure. We sought to establish easily derived VO₂Rec measures and evaluate their cardiospecificity and prognostic relevance in patients with dyspnea on exertion.
Campain J, Griskowitz C, Newlands C, Claggett BL, Kulac IJ, McGinnis S, Giverts I, Moreno F, Minasian A, Prasad C, Rupert L, Landsteiner I, Iskenderian N, Coats CJ, Lee MMY, Maron MS, Owens AT, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Wohltman A, Malhotra R, Lewis GD.   +23 more
europepmc   +2 more sources

Metabolite‐sensitive cross‐bridge models of human atria reveal the impact of diabetes on muscle mechanoenergetics

The Journal of Physiology, EarlyView.
Abstract figure legend In this study, we used mathematical modelling to explore the effect of diabetes on muscle mechanoenergetics. Our parameterisation of cross‐bridge models using data from non‐diabetic and diabetic human atrial tissues revealed lower values for cross‐bridge stiffness, detachment rates, attachment rates and lower ATP sensitivity in ...
Julia H. Musgrave, June‐Chiew Han, Marie‐Louise Ward, Andrew J. Taberner, Kenneth Tran   +4 more
wiley   +1 more source

Translating cardiovascular ion channel and Ca2+ signalling mechanisms into therapeutic insights

The Journal of Physiology, EarlyView.
Abstract figure legend This white paper integrates mechanistic discoveries across ion channel biology, Ca2+ signalling and multiscale cardiovascular physiology to highlight new opportunities for accelerating research and guiding next‐generation therapies. Printed with permission from ®Anita Impagliazzo Medical Illustration. [Correction added on 2 March
Silvia Marchianò, Miguel Martín‐Aragón Baudel, Charlotte E. R. Smith, Gonzalo Hernandez Hernandez, Donald M. Bers, Patrick M. Boyle, Dobromir Dobrev, Shanna Hamilton, Osama F. Harraz, Na Li, Thomas A. Longden, William E. Louch, Madeline Nieves‐Cintron, Matthew A. Nystoriak, Walter Lee Murfee, Przemysław B. Radwański, Swapnil K. Sonkusare, Manuel F. Navedo, Eleonora Grandi   +18 more
wiley   +1 more source

Evaluation of Percutaneous Intramyocardial Septal Pulsed Field Ablation in a Rabbit Model: Safety, Efficacy, and Feasibility

Journal of Interventional Cardiology, Volume 2026, Issue 1, 2026.
Background Percutaneous intramyocardial (PIM) septal pulsed field ablation (SPFA) represents an innovative technique for the management of hypertrophic obstructive cardiomyopathy. However, the paucity of pertinent animal models has impeded comprehensive investigation. This study aimed to assess the safety, efficacy, and feasibility of PIM‐SPFA, as well
Xing-an Zhao, Hua-lei Dai, Si-ming Tao, Yi-jian Zhang, Ji Jia, Li-juan Song, Man Yang, Yun-na Ge, Xi-ya Wang, Juan Qing, Piotr Musialek   +10 more
wiley   +1 more source

Yield of Genetic Testing in Pediatric Cardiomyopathies: Implications for Novel Therapeutic Options

Molecular Genetics &Genomic Medicine, Volume 13, Issue 7, July 2025.
Pediatric cardiomyopathies are rare, heterogeneous, and challenging conditions, often with a genetic etiology. We estimated the yield of genetic testing in a pediatric cohort with cardiomyopathies and evaluated the potential candidacy to current or emerging treatments based on genetic results. Over one‐third had a conclusive genetic test, including 25%
Adelaide Ballerini, Francesca Girolami, Alessia Gozzini, Silvia Passantino, Mattia Zampieri, Alberto Marchi, Alessia Tomberli, Giovanni B. Calabri, Gaia Spaziani, Giulio Porcedda, Elena Bennati, Silvia Favilli, Iacopo Olivotto   +12 more
wiley   +1 more source

Hypertrophic Cardiomyopathy: Current Perspectives

Reviews in Cardiovascular Medicine
Hypertrophic cardiomyopathy (HCM) is a multifaceted genetic disorder characterized by left ventricular hypertrophy (LVH) in the absence of alternative causes, with an estimated prevalence ranging from 1 in 200 to 1 in 500 individuals. Since HCM was first
Dhruvil Patel, Ruchika Bhargav, Aliaa Mousa, Sabahat Bokhari   +3 more
doaj   +1 more source

Efficacy and Safety of Percutaneous Transluminal Septal Myocardial Ablation Treating Hypertrophic Cardiomyopathy: Systematic Review and Meta‐Analysis

International Journal of Clinical Practice, Volume 2025, Issue 1, 2025.
Background: Percutaneous transluminal septal myocardial ablation (PTSMA) is one of the invasive therapeutic measures for the treatment of patients with obstructive hypertrophic cardiomyopathy (HCM). Objective: To systematically evaluate the efficacy and safety of PTSMA in patients with HCM.
Sun Qinyu, Deng Yifan, Yu Jiling, Zhang Zhaoyuan, Cao Gan, Yang Tianxiao, Fang Zhen, Ji Jun, He Shenghu, Zhang Jing, Luigi Sciarra   +10 more
wiley   +1 more source

Efficacy and Safety of Selective Cardiac Myosin Inhibitors in the Treatment of Hypertrophic Cardiomyopathy: a Meta-analysis [PDF]

Zhongguo quanke yixue
Background Hypertrophic cardiomyopathy (HCM) is a genetic disorder, characterized primarily by left ventricular outflow tract obstruction and asymmetric myocardial hypertrophy, which predisposes to sudden cardiac death and malignant arrhythmias. Although
ZHANG Huijuan, LI Xinghui, ZHANG Xiaoming, YIN Long, SHAO Long
doaj   +1 more source

Cardiomyopathy: pathogenesis and therapeutic interventions

MedComm, Volume 5, Issue 11, November 2024.
Cardiomyopathy is a group of diseases characterized by structural and functional damage to the myocardium. Many specific gene mutations, environmental factors, and metabolic disorders may cause cardiomyopathy. Traditional therapeutic includes drug and surgery. With the growing comprehension of the molecular mechanisms underlying cardiomyopathy.
Shitong Huang, Jiaxin Li, Qiuying Li, Qiuyu Wang, Xianwu Zhou, Jimei Chen, Xuanhui Chen, Abdelouahab Bellou, Jian Zhuang, Liming Lei   +9 more
wiley   +1 more source

Assessing the Applicability of Cardiac Myosin Inhibitors for Hypertrophic Cardiomyopathy Management in a Large Single Center Cohort

Reviews in Cardiovascular Medicine
Background: Cardiac myosin inhibitors (CMIs), including Mavacamten and Aficamten, have emerged as a groundbreaking treatment for hypertrophic cardiomyopathy (HCM).
Ali Amr, Elham Kayvanpour, Christoph Reich, Jan Koelemen, Shamily Asokan, Norbert Frey, Benjamin Meder, Farbod Sedaghat-Hamedani   +7 more
doaj   +1 more source